10 New Biologic Therapies for Eosinophilic Esophagitis

Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder that affects the esophagus, leading to symptoms such as difficulty swallowing, chest pain, and heartburn. While traditional treatments like steroids and diet modifications can help manage the condition, there are also new biologic therapies that show promise in treating EoE. Here are 10 of the latest biologic therapies being studied for EoE:

  1. Benralizumab: This biologic therapy targets and depletes eosinophils, a type of white blood cell that plays a key role in EoE inflammation. Clinical trials have shown promising results in reducing symptoms and improving esophageal function in patients with EoE.
  2. Reslizumab: Another biologic therapy that targets eosinophils, reslizumab has been shown to reduce esophageal inflammation and improve symptoms in patients with EoE. It is currently being studied in clinical trials.
  3. Mepolizumab: This biologic therapy targets interleukin-5, a protein that helps regulate eosinophil levels in the body. Clinical trials have shown that mepolizumab can reduce esophageal inflammation and improve symptoms in patients with EoE.
  4. Tralokinumab: Tralokinumab is a biologic therapy that targets interleukin-13, a protein that is involved in the inflammation process in EoE. Clinical trials have shown that tralokinumab can reduce esophageal inflammation and improve symptoms in patients with EoE.
  5. IL-4/IL-13 dual inhibitor: This biologic therapy targets both interleukin-4 and interleukin-13, two proteins that are involved in the inflammation process in EoE. Clinical trials have shown promising results in reducing esophageal inflammation and improving symptoms in patients with EoE.
  6. Anti-Siglec-8 antibody: Siglec-8 is a protein that is expressed on the surface of eosinophils and plays a role in their activation. An anti-Siglec-8 antibody has been developed as a biologic therapy for EoE and is currently being studied in clinical trials.
  7. Anti-TSLP antibody: Thymic stromal lymphopoietin (TSLP) is a protein that helps regulate the immune response in EoE. An anti-TSLP antibody has been developed as a biologic therapy for EoE and is currently being studied in clinical trials.
  8. Anti-IL-13 antibody: Interleukin-13 is a protein that plays a key role in the inflammation process in EoE. An anti-IL-13 antibody has been developed as a biologic therapy for EoE and is currently being studied in clinical trials.
  9. Anti-IL-5 antibody: Interleukin-5 is a protein that helps regulate eosinophil levels in the body. An anti-IL-5 antibody has been developed as a biologic therapy for EoE and is currently being studied in clinical trials.
  10. Anti-IL-4 antibody: Interleukin-4 is a protein that is involved in the inflammation process in EoE. An anti-IL-4 antibody has been developed as a biologic therapy for EoE and is currently being studied in clinical trials.

While these new biologic therapies show promise in treating EoE, it is important to note that they are still in the early stages of development and may not be widely available yet. Talk to your doctor about the best treatment options for your EoE and whether you may be a candidate for one of these new biologic therapies.